American Society of Clinical Oncology guidelines for the clinical use of hematopoietic colony-stimulating factors

Current Opinion in Hematology

Volumn 3, Issue 1, 1996, Pages 3-10

  Ozer, Howard ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER RESEARCH; CLINICAL TRIAL; HEMATOPOIESIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDICAL SOCIETY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 0029995544     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199603010-00002     Document Type: Review

References (64)

1. Ozer H, Miller LL, Anderson JR, Anderson PN, Armitage JO, Beckhardt S, Bennett CL, Bodey GP, Crawford J, Davidson NE, et al.: American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. Adopted on September 13, 1994 by the American Society of Clinical Oncology. J Clin Oncol 1994, 12:24171-2508.
2. Canadian Medical Association: The Canadian task force on the periodic health examination. Can Med Assoc J 1979, 121:1193-1254.
3. Sackett DL: Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1989, 95(suppl 2):2-4.
4. Cook DL, Guyatt GH, Laupacia A, et al.: Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1992, 102(suppl 4):305-311. See erratum in Chest 1994, 105:647.
5. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G, et al.: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer (r-metHuG-CSF). N Engl J Med 1991, 325:164-170.
6. Dillman RO, Davis RB, Green MR, Weiss RB, Gottlieb AJ, Caplan S, Kopel S, Preisler H, McIntyre OR, Schiffer C: A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood 1991, 78:2520-2526.
7. Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA, et al.: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992, 10:1066-1073.
8. Budman DR, Korzun AH, Aisner J, Younger J, Silver R, Costanza M, Rice MA, Wood W: A feasibility study of intensive CAF as outpatient adjuvant therapy for stage II breast cancer in a cooperative group: CALGB 8443. Cancer Invest 1990, 8:571-575.
9. Gerstner J, O'Connell MJ, Wieand HS, et al.: A prospectively randomized clinical trial comparing 5-FU combined with either high-or low-dose leucovorin for the treatment of advanced colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1991, 10:134.
10. Nichols CR, Williams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlaufer J, Miller ME, Bartolucci A, Schacter L, Einhorn LH: Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991, 9:1163-1172.
11. Forastiere AA, Metch B, Schullen DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK, et al.: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992, 10:1245-1251.
12. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun GO, et al.: Randomized study of cyclophosphamide, doxorubicin and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992, 10:228-291.
13. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med 1992, 327:1478-1484.
14. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993, 328:1002-1006.
15. Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, Surwit EA, Malvlya VK, Nahhas WA, Jolles CJ: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992, 10:706-717.
16. Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, Depierre A, Johnson P, Decoster G, Tomita D, et al.: Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993, 29:319-324.
17. Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wilkinson PM, Kane K, Bentley J, Crowther D: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992, 80:1430-1436.
18. Gebbia V, Testa A, Valenza R, Borsellino N, Cipolla C, Cannata G, Curto G, Latten M, Florena M, Gebbia N: A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma. J Chemother 1993, 5:186-190.
19. Gerhartz HH, Engelhard M, Meusers P, Brittinger G, Wilmanns W, Schlimok G, Mueller P, Huhn D, Musch R, Siegert W, et al.: Randomized, double-blind-placebo-controlled phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 1993, 82:2329-2339.
20. Hamm JT, Schiller JH, Oken MM, et al.: Granulocyte-macrophage colony-stimulating factor (GM-CSF) in small cell carcinoma of the lung (SCCL): preliminary analysis of a randomized controlled trial [abstract]. Proc Am Soc Clin Oncol 1991, 10:255.
21. Hamm JT, Schiller J, Oken MM, et al.: Dose ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small cell lung cancer. Proc Am Soc Clin Oncol 1993, 12:335.
22. Nichols C, Bajorin D, Schmoll HJ, et al.: VIP chemotherapy with/without GM-CSF for poor risk, relapsed or refractory germ cell tumors (GCT): preliminary analysis of a randomized controlled trial [abstract]. Proc Am Soc Clin Oncol 1991, 10:167.
23. Bunn PA, Crowley J, Hazuka M, et al.: The role of GM-CSF in limited stage SCLC: a randomized phase III study of the Southwest Oncology Group (SWOG) [abstract]. Proc Am Soc Clin Oncol 1992, 11:292.
24. Lyman GH, Lyman CG, Sanderson RA, Balducci L: Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993, 85:1935-1936.
25. Glaspy J, Bleecker G, Crawford J, et al.: The impact of therapy with recombinant granulocyte colony-stimulating factor (G-CSF) on the health care costs associated with cancer chemotherapy [abstract]. Blood 1991, 78(suppl):7a.
26. Zinzani PL for the Lymphoma Italian Cooperative Study Group: Randomized multicenter trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1994, 84(suppl 1).
27. Fossa S, Kaye SB, Mead GM, Cullen M, DeWitt R, Bodrogi I, van Groeninger C, Sylvester R, Stenning S, Vermeylen K, Lallemand E, de Mulder P: An MRC/EORTC randomized trial in poor prognosis metastatic teratoma, comparing treatment with/without filgrastim (G-CSF). Proc Am Soc Clin Oncol 1995, 14:656.
28. Glaspy JA, Bleecker G, Crawford J, Stoller R, Strauss M: The Impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer 1993, 29A:23-30.
29. Zagonal V, Barbare R, Merola MC, Talamini R, Lazzarin R, Tirelli U, Carbone A, Monfardini S: Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. Ann Oncol 1994 5(suppl 2):127-132.
30. Riikonen P, Rahiala J, Salonvaara M, Perkkio M: Prophylactic administration of granulocyte colony-stimulating factor (Filgrastim) after conventional chemotherapy in children with cancer. Stem Cells 1995, 13:289-294.
31. Dranitsaris, Sutcliffe SB: Economic analysis of prophylactic G-CSF after mini-Beam salvage chemotherapy for Hodgkin's and non-Hodgkins lymphoma. Leuk Lymphoma 1995, 17:139-145.
32. Figueredo AT, Hryniuk WM, Strautmanis I, et al.: Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 1985, 3:54-64.
33. Cebon J, Layton J, Pavlovic R, et al.: Endogenous cytokine production in response to sepsis in neutropenic and non-neutropenic patients [abstract]. Blood 1991, 78(suppl 1):8a.
34. Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Chawla SP, Fenoglio C, Cooper S, Buescher ES, Frenck RW Jr, Holian A, et al.: Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol 1992, 10:1266-1277.
35. Kaplan LD, Kahn JO, Crowe F, Northfelt D, Neville P, Grossberg H, Abrams DI, ,Tracey J, Mills J, Volberding PA: Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. J Clinic Oncol 1991, 9:929-940.
36. Clark DA, Neidhart JA: Granulocyte-macrophage colony-stimulating factor with dose-intensified treatment of cancer. Semin Hematol 1992, 29(suppl 3):27-32.
37. Miller LL: Current status of G-CSF in support of chemotherapy and radiotherapy. Oncology 1993, 10:67-88.
38. Heil G, Hoetzer D, Sanz MA, Lechner K, Liu Yin J, Papa G, Noens L, Ho J, O'Brien C, Matcham J: Results of a randomized, double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de-novo acute myeloid leukaemia [abstract]. Blood 1995, 86(suppl):267a.
39. Goodwin JE, Kopecky KJ, Head DR, Hynes HE, Balcerzak SP, Appelbaum FR: A double-blind placebo controlled trial of G-CSF in elderly patients with previously untreated acute myeloid leukemia. A southwest Oncology Group Study [abstract]. Blood 1995, 86(suppl 1):434a.
40. Rowe JM, Anderson JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA, Wiernik PH: A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia : a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995, 86:457-462.
41. Monic F, Kraut M, Lurin P, et al.: Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1992, 11:294.
42. Fushiki M, Abe M: Randomized double-blind controlled study of rhG-CSF in patients with neutropenia induced by radiation therapy [abstract]. Proc Am Soc Clin Oncol 1992, 11:410.
43. Knox SJ, Fowler S, Marquez C, Hoppe RT: Effect of filgrastim (G-CSF) in Hodgkin's disease patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 1994, 28:445-450.
44. Furman W, Fairclough D, Huhn R, Pratt CB, Stute N, Petros WP, Evans WE, Bowman LC, Douglass EC, Santana VM, et al.: Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy. J Clin Oncol 1991, 9:1022-1028.
45. Riikonen P, Saarinen UM, Makipernaa A, et al.: rhGM-CSF in the treatment of fever and neutropenia: a double-blind, placebo-controlled study in children with malignancy [abstract]. Proc Am Soc Clin Oncol 1993, 12:442.
46. Blazer B, Kersey J, McGlave P, Vallera DA, Lasky LC, Haake RJ, Bostrom B, Weisdorf DR, Epstein C, Ramsay NK: In vivo administration of recombinant human granulocyte-macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts. Blood 1989, 73:849-857.
47. Smith MA, Horowitz ME, Balis F, et al.: Pediatric experience with granulocyte macrophage colony-stimulating factor (GM-CSF): pharmacokinetics and cytokine induction [abstract]. Proc Am Assoc Cancer Res 1991, 32:196.
48. Marks LB, Friedman HS, Kurizberg J, Oakes WJ, Hockenberger BM: Reversal of radiation-induced neutropenia by granulocyte colony-stimulating factor. Med Pediatr Oncol 1992, 20:240-242.
49. Stute N, Santana VM, Rodman JH, Schell MJ, Ihle JN, Evans WE: Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood 1992, 79:2849-2854.
50. Michon J, Hartmann O, Bouffet E, et al.: Preliminary analysis of the first open label randomized phase III study of recombinant colony stimulating factor as an adjunct to combination induction chemotherapy in pediatric patients with metastatic neuroblastoma [abstract]. Blood 1992, 10(suppl 1):248a.
51. Weinthal J, Gillan E, Hodder F, et al.: G-CSF significantly reduces the nadir of neutropenia, hospitalizations and costs during intensive chemotherapy in children with solid tumors [abstract]. Proc Am Soc Clin Oncol 1992, 11:362.
52. Santana VM, Bowman L, Furman W, et al.: Trial of chemotherapy plus recombinant G-CSF in children with advanced neuroblastoma [abstract]. Med Pediatr Oncol 1990, 18:395.
53. Stork L, Busselmaier C, Odom L, et al.: IV G-CSF has similar efficacy to SQ G-CSF in pediatric patients [abstract]. Proc Am Soc Clin Oncol 1993, 12:439.
54. Shen WP, Gillan E, Tishier D, et al.: A pilot study evaluating the toxicity and response rate of ifosfamide, carboplatin and etoposide (ICE) chemotherapy with G-CSF support for recurrent pediatric solid tumors [abstract]. Proc Am Soc Clin Oncol 1993, 12:426.
55. Fukuda M, Kojima S, Matsumoto K, Matsuyama T: Autotransplantation of peripheral blood stem cells mobilized by chemotherapy and recombinant human granulocyte colony-stimulating factor in childhood neuroblastoma, and non-Hodgkin's lymphoma. Br J Haematol 1992, 80:327-331.
56. Marina N, Shema S, Roadman J, et al.: Ifosfamide, carboplatin and etoposide (ICE) combined with human granulocyte-macrophage colony-stimulating factor (GM-CSF) in children with recurrent solid tumors [abstract]. Proc Am Soc Clin Oncol 1993, 12:422.
57. Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MA, Clarkson B, et al.: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988, 318:1414-1422.
58. Maugard-Louboutin C, Chastang C, Chevallier B, et al.: Dose-effect relationship of granulocyte colony stimulating factor (G-CSF): PE 2601 in patients (pts) with advanced breast carcinoma (ABC) treated by intensive chemotherapy [abstract]. Proc Am Soc Clin Oncol 1993, 12:90.
59. Eguchi K, Shinkai T, Sasaki Y, Tamura T, Ohe Y, Nakagawa K, Fukuda M, Yamada K, Kojima A, Oshita F, et al.: Subcutaneous administration of recombinant human granulocyte colony-stimulating factor (KRN8601) in intensive chemotherapy for patients with advanced lung cancer. Jpn J Cancer Res 1990, 81:1168-1174.
60. Eguchi K, Sasaki S, Tamura T: Dose escalation study of recombinant human granulocyte colony-stimulating factor (KRN8601) in patients with advanced malignancy. Cancer Res 1989, 49:5221-5224.
61. Kaneko T, Takaku F, Ogawa M: Outline of clinical studies on recombinant human granulocyte colony stimulating factor (KRN8601) in Japan. Tokai J Exp Clin Med 1991, 16:51-61.
62. Kudoh S, Fukuoka M, Negoro S, Tanaka H, Kusunoki Y, Matsui K, Masuda N, Takifugi N, Itoh K, Nishioka M, et al.: Weekly dose-intensive chemotherapy in patients with small-cell lung cancer: a pilot study. Am J Clin Oncol 1992, 15:29-34.
63. Ogawa M, Masaoka T, Takaku F: Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on leukopenia induced by chemotherapy for malignant lymphomas [abstract]. Proc Am Soc Clin Oncol 1990, 9:76.
64. Fukuoka M, Takada M, Masuda N, et al.: Dose intensive weekly chemotherapy (CT) with or without recombinant human granulocyte colony-stimulating factor (G-CSF) in extensive stage (ES) small-cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol 1992, 11:290.